Teva and alvotech announce fda approval of interchangeability for selarsdi™ (ustekinumab-aekn) with stelara® (ustekinumab)

Parsippany, n.j. & reykjavÍk, iceland, may 05, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and alvotech (nasdaq: alvo) today announced that the u.s. food and drug administration (fda) has approved selarsdi™ (ustekinumab-aekn) injection as interchangeable with the reference biologic stelara® (ustekinumab). as of april 30, 2025, selarsdi is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as crohn's disease, and ulcerative colitis.
TEVA Ratings Summary
TEVA Quant Ranking